Cargando…

6′-Sialyllactose Ameliorates In Vivo and In Vitro Benign Prostatic Hyperplasia by Regulating the E2F1/pRb–AR Pathway

Background: 6′-Sialyllactose (6SL) displays a wide range of the bioactive benefits, such as anti-proliferative and anti-angiogenic activities. However, the therapeutic effects of 6SL on benign prostatic hyperplasia (BPH) remain unknown. Methods: Six-week-old male Wistar rats (n = 40) were used for i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Bo-Ram, Kim, Hyo-Jung, Kim, Eun-Yeong, Chung, Tae-Wook, Ha, Ki-Tae, An, Hyo-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770807/
https://www.ncbi.nlm.nih.gov/pubmed/31547405
http://dx.doi.org/10.3390/nu11092203
_version_ 1783455567236300800
author Jin, Bo-Ram
Kim, Hyo-Jung
Kim, Eun-Yeong
Chung, Tae-Wook
Ha, Ki-Tae
An, Hyo-Jin
author_facet Jin, Bo-Ram
Kim, Hyo-Jung
Kim, Eun-Yeong
Chung, Tae-Wook
Ha, Ki-Tae
An, Hyo-Jin
author_sort Jin, Bo-Ram
collection PubMed
description Background: 6′-Sialyllactose (6SL) displays a wide range of the bioactive benefits, such as anti-proliferative and anti-angiogenic activities. However, the therapeutic effects of 6SL on benign prostatic hyperplasia (BPH) remain unknown. Methods: Six-week-old male Wistar rats (n = 40) were used for in vivo experiments. All rats were castrated and experimental BPH was induced in castrated rats by intramuscular injection of testosterone, with the exception of those in the control group. Rats with BPH were administrated finasteride and 0.5 or 1.0 mg/kg 6SL. Furthermore, the inhibitory effects of 6SL on human epithelial BPH cell line (BPH-1) cells were determined in vitro. Results: Rats with BPH exhibited outstanding BPH manifestations, including prostate enlargement, histological alterations, and increased prostate-specific antigen (PSA) levels. Compared to those in the BPH group, rats in the 6SL group showed fewer pathological changes and normal androgen events, followed by restoration of retinoblastoma protein (pRb) and cell cycle-related proteins. In BPH-1 cells, treatment with 6SL significantly suppressed the effects on the androgen receptor (AR), PSA, and E2F transcription factor 1 (E2F1)-dependent cell cycle protein expression. Conclusions: 6SL demonstrated anti-proliferative effects in a testosterone-induced BPH rat model and on BPH-1 cells by regulating the pRB/E2F1–AR pathway. According to our results, we suggest that 6SL may be considered a potential agent for the treatment of BPH.
format Online
Article
Text
id pubmed-6770807
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67708072019-10-30 6′-Sialyllactose Ameliorates In Vivo and In Vitro Benign Prostatic Hyperplasia by Regulating the E2F1/pRb–AR Pathway Jin, Bo-Ram Kim, Hyo-Jung Kim, Eun-Yeong Chung, Tae-Wook Ha, Ki-Tae An, Hyo-Jin Nutrients Article Background: 6′-Sialyllactose (6SL) displays a wide range of the bioactive benefits, such as anti-proliferative and anti-angiogenic activities. However, the therapeutic effects of 6SL on benign prostatic hyperplasia (BPH) remain unknown. Methods: Six-week-old male Wistar rats (n = 40) were used for in vivo experiments. All rats were castrated and experimental BPH was induced in castrated rats by intramuscular injection of testosterone, with the exception of those in the control group. Rats with BPH were administrated finasteride and 0.5 or 1.0 mg/kg 6SL. Furthermore, the inhibitory effects of 6SL on human epithelial BPH cell line (BPH-1) cells were determined in vitro. Results: Rats with BPH exhibited outstanding BPH manifestations, including prostate enlargement, histological alterations, and increased prostate-specific antigen (PSA) levels. Compared to those in the BPH group, rats in the 6SL group showed fewer pathological changes and normal androgen events, followed by restoration of retinoblastoma protein (pRb) and cell cycle-related proteins. In BPH-1 cells, treatment with 6SL significantly suppressed the effects on the androgen receptor (AR), PSA, and E2F transcription factor 1 (E2F1)-dependent cell cycle protein expression. Conclusions: 6SL demonstrated anti-proliferative effects in a testosterone-induced BPH rat model and on BPH-1 cells by regulating the pRB/E2F1–AR pathway. According to our results, we suggest that 6SL may be considered a potential agent for the treatment of BPH. MDPI 2019-09-12 /pmc/articles/PMC6770807/ /pubmed/31547405 http://dx.doi.org/10.3390/nu11092203 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jin, Bo-Ram
Kim, Hyo-Jung
Kim, Eun-Yeong
Chung, Tae-Wook
Ha, Ki-Tae
An, Hyo-Jin
6′-Sialyllactose Ameliorates In Vivo and In Vitro Benign Prostatic Hyperplasia by Regulating the E2F1/pRb–AR Pathway
title 6′-Sialyllactose Ameliorates In Vivo and In Vitro Benign Prostatic Hyperplasia by Regulating the E2F1/pRb–AR Pathway
title_full 6′-Sialyllactose Ameliorates In Vivo and In Vitro Benign Prostatic Hyperplasia by Regulating the E2F1/pRb–AR Pathway
title_fullStr 6′-Sialyllactose Ameliorates In Vivo and In Vitro Benign Prostatic Hyperplasia by Regulating the E2F1/pRb–AR Pathway
title_full_unstemmed 6′-Sialyllactose Ameliorates In Vivo and In Vitro Benign Prostatic Hyperplasia by Regulating the E2F1/pRb–AR Pathway
title_short 6′-Sialyllactose Ameliorates In Vivo and In Vitro Benign Prostatic Hyperplasia by Regulating the E2F1/pRb–AR Pathway
title_sort 6′-sialyllactose ameliorates in vivo and in vitro benign prostatic hyperplasia by regulating the e2f1/prb–ar pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770807/
https://www.ncbi.nlm.nih.gov/pubmed/31547405
http://dx.doi.org/10.3390/nu11092203
work_keys_str_mv AT jinboram 6sialyllactoseamelioratesinvivoandinvitrobenignprostatichyperplasiabyregulatingthee2f1prbarpathway
AT kimhyojung 6sialyllactoseamelioratesinvivoandinvitrobenignprostatichyperplasiabyregulatingthee2f1prbarpathway
AT kimeunyeong 6sialyllactoseamelioratesinvivoandinvitrobenignprostatichyperplasiabyregulatingthee2f1prbarpathway
AT chungtaewook 6sialyllactoseamelioratesinvivoandinvitrobenignprostatichyperplasiabyregulatingthee2f1prbarpathway
AT hakitae 6sialyllactoseamelioratesinvivoandinvitrobenignprostatichyperplasiabyregulatingthee2f1prbarpathway
AT anhyojin 6sialyllactoseamelioratesinvivoandinvitrobenignprostatichyperplasiabyregulatingthee2f1prbarpathway